Based on data of the British Leukemia registries published in the year 2000, the incidence of APL was reported to be very low in children below the age of 10 years.
Very recently, an 86-year-old Chinese patient with newly diagnosed APL was reported, who entered molecular remission after 60 days of treatment with low-dose ATO (0.05 mg/kg/day) followed by low-dose ATRA (15 mg/m/day [ 50]).
In the report of the APL 93 study, results of 34 (6 %) patients over 70 years were included.
As statistically significant findings associated with CD56+ APL in previous reports were not the same as our present study, further studies with sufficient numbers of patients will be needed to clarify the characteristic features of CD56+ APL.
A Liberian-flagged merchant vessel, the APL Bahrain, was reported by The Australian, a daily newspaper, to have rescued the first group of six survivors, all of them men.
Of note, a novel line immunoassay (LIA) offering the opportunity to test for several aPL has been reported [16, 21].
The divergent aPL associations previously reported are likely to be due to methodological issues, as different assays for aPL and LA detection have been used and cut-off values have varied between studies.
Many traditionally medicinal plants and natural products have been tested for their inhibition of α-glucosidase activities and anti-diabetic potential [ 10], but few researches about APL have been reported.
Several anatomic studies and one clinical study have reported supernumerary APL or EPB tendons and an accessory compartment as suspected causes of increased gliding resistance in dQ patients resulting in an inflammatory response [ 34– 34].
The great majority of clinical reports on APL have focused on the progress of the younger age groups.
